Halozyme Therapeutics, Inc. (NASDAQ: HALO) will release its first‑quarter 2026 financial and operating results on May 11 2026. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results.
The announcement, issued on April 30 2026, follows a period of strong growth for Halozyme. In Q1 2025 the company reported revenue of $264.9 million, up 35 % from $195.9 million in Q1 2024, and operating income of $141.5 million, a 48 % increase from the prior year. The company’s record full‑year 2025 revenue of $1.397 billion and its reiterated 2026 guidance—projecting total revenue of $1.71 billion to $1.81 billion—highlight a 22 % to 30 % growth outlook.
Halozyme’s performance is driven by its ENHANZE® drug‑delivery platform, which enables subcutaneous administration of biologics, and by the recent expansion of its portfolio to include Hypercon™ and Surf Bio’s hyperconcentration technology. The company’s partnership network—spanning Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, and Bristol‑Myers Squibb—continues to generate royalty revenue from key products such as DARZALEX SC, Phesgo, and VYVGART Hytrulo. These drivers underpin the company’s revenue momentum and support its guidance for 2026.
While the announcement itself is a routine earnings‑release notice, the context of Halozyme’s growth trajectory, technology expansion, and partnership ecosystem provides investors with a clearer view of the company’s near‑term prospects and the strategic initiatives that are likely to sustain its revenue and margin expansion in the coming quarters.
The company’s management reiterated its confidence in the 2026 outlook, noting that the combination of its core ENHANZE platform and the new Hypercon technology positions Halozyme to capture additional market share in the subcutaneous delivery space. The guidance reflects expectations of continued demand growth and operational leverage, while the company remains focused on maintaining margin expansion through cost discipline and efficient scaling of its technology portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.